Axovant Sciences Ltd. (NYSE:AXON)‘s stock had its “buy” rating restated by equities research analysts at JMP Securities in a research report issued on Tuesday.

AXON has been the topic of a number of other research reports. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $15.00 target price on the stock in a report on Tuesday, October 18th. HC Wainwright reaffirmed a “buy” rating on shares of Axovant Sciences in a report on Wednesday, August 17th. Robert W. Baird reaffirmed an “outperform” rating and set a $29.00 target price on shares of Axovant Sciences in a report on Friday, September 23rd. Jefferies Group reaffirmed a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a report on Monday, September 26th. Finally, Evercore ISI reaffirmed a “buy” rating and set a $29.00 target price on shares of Axovant Sciences in a report on Friday, September 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $26.33.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Axovant Sciences (NYSE:AXON) opened at 12.38 on Tuesday. The stock’s 50 day moving average is $13.41 and its 200-day moving average is $13.76. The firm’s market cap is $1.23 billion. Axovant Sciences has a one year low of $8.86 and a one year high of $21.30.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings results on Monday, August 15th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.02. On average, equities research analysts expect that Axovant Sciences will post ($1.68) earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of AXON. BlackRock Inc. raised its position in shares of Axovant Sciences by 4.7% in the first quarter. BlackRock Inc. now owns 36,659 shares of the company’s stock worth $421,000 after buying an additional 1,659 shares during the last quarter. BlackRock Group LTD raised its position in Axovant Sciences by 2.1% in the first quarter. BlackRock Group LTD now owns 148,704 shares of the company’s stock valued at $1,707,000 after buying an additional 3,126 shares in the last quarter. Strs Ohio raised its position in Axovant Sciences by 960.9% in the second quarter. Strs Ohio now owns 48,800 shares of the company’s stock valued at $626,000 after buying an additional 44,200 shares in the last quarter. Alps Advisors Inc. raised its position in Axovant Sciences by 24.9% in the second quarter. Alps Advisors Inc. now owns 139,286 shares of the company’s stock valued at $1,788,000 after buying an additional 27,780 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new position in Axovant Sciences during the second quarter valued at approximately $682,000. 29.43% of the stock is currently owned by hedge funds and other institutional investors.

About Axovant Sciences

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

5 Day Chart for NYSE:AXON

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.